Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Ponatinib (hydrochloride)

Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively[1].

Product Specifications

CAS Number

[1114544-31-8]

Product Name Alternative

AP24534 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H301, H313, H333, H335, H361, H372

Target

Autophagy; Bcr-Abl; FGFR; PDGFR; Src; VEGFR

Type

Reference compound

Related Pathways

Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/ponatinib-hydrochloride.html

Purity

99.76

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC=C(C)C(C#CC2=CN=C3C=CC=NN23)=C1)NC4=CC=C(CN5CCN(CC5)C)C(C(F)(F)F)=C4.Cl

Molecular Formula

C29H28ClF3N6O

Molecular Weight

569.02

Precautions

H301, H313, H333, H335, H361, H372

References & Citations

[1]O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16 (5), 401-412.|[2]Gover-Proaktor A, et al. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma. 2017 Jun;58 (6) :1455-1467.|[3]Hong YP, et al. Effects of Castanospermine on Inflammatory Response in a Rat Model of Experimental Severe Acute Pancreatitis. Arch Med Res. 2016 Aug;47 (6) :436-445.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

Abl; PDGFRα; VEGFR2/KDR/Flk-1

Citation 01

Biomaterials. 2022 Oct:289:121800.|Acta Pharm Sin B. 2023 Oct;13 (10) :4253-4272.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Biochem Pharmacol. 2021 Oct:192:114710.|Biomed Pharmacother. 2024 Nov:180:117569.|Biomed Pharmacother. 2025 Jun 20:189:118246.|Biomolecules. 2022 Jun 11;12 (6) :819.|bioRxiv. 2024 Apr 21.|bioRxiv. 2025 February 26.|bioRxiv. 2025 May 5:2025.04.30.651490.|bioRxiv. 2025 Sep 30.|Blood Vessel Thromb Hemost. 2025 Nov 17.|BMC Chem. 2025 Aug 22;19 (1) :248.|Cancer Discov. 2021 Jan;11 (1) :126-141.|Cancer Sci. 2025 Apr;116 (4) :1115-1125.|Cell Rep Med. 2025 Apr 2:102053.|Clin Chim Acta. 2018 May:480:180-185.|Commun Biol. 2024 Jul 10;7 (1) :843.|Eur J Pharmacol. 2020 Dec 15;889:173292.|Exp Hematol. 2014 May;42 (5) :369-379.e3.|Fundam Clin Pharmacol. 2021 Oct;35 (5) :919-929.|Harvard Medical School LINCS LIBRARY|Heliyon. 2024 Sep 28;10 (19) :e38637.|Int J Biol Macromol. 2024 Dec 2:138305.|J Chem Eng Data. 2024 Jun 10.|J Ethnopharmacol. 2023 Jun 12:309:116275.|J Ethnopharmacol. 2024 Apr 6:323:117669.|J Ethnopharmacol. 2025 Sep 17;355 (Pt A) :120621.|J Hypertens. 2025 May 1;43 (5) :827-840.|J Inflamm Res. 2025 Jun 26:18:8447-8475.|J Med Chem. 2019 May 23;62 (10) :5006-5024. |J Med Chem. 2024 Nov 28;67 (22) :20571-20579.|Leuk Res. 2016 Jun:45:24-32.|Neurosci Bull. 2020 Mar;36 (3) :263-276.|Pharmaceuticals (Basel) . 2022 Aug 29;15 (9) :1073.|Pharmacogn Mag. 2023 Jul 20.|PLoS One. 2021 Sep 30;16 (9) :e0258140.|PLoS One. 2022 Feb 14;17 (2) :e0263822.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Research Square Preprint. 2021 May.|Research Square Print. 2023 Mar 23.|Sci Rep. 2025 Jul 2;15 (1) :22961.|Sci Rep. 2025 Oct 16;15 (1) :36227.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Target Oncol. 2020 Oct;15 (5) :659-671.|Technical University of Munich. 24.01.2018.|University of Pittsburgh. 2025.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Recombinant Human OSM
P1542-01 50 µg

Recombinant Human OSM

Ask
View Details
Recombinant Human OSM
P1542-02 200 µg

Recombinant Human OSM

Ask
View Details
Recombinant Human OSM
P1542-03 1 mg

Recombinant Human OSM

Ask
View Details
RGAG4 CRISPRa sgRNA lentivector (set of three targets)(Human)
38893121 3x 1.0µg DNA

RGAG4 CRISPRa sgRNA lentivector (set of three targets)(Human)

Ask
View Details
ATXN7L3B Polyclonal Antibody, PE-Cy5 Conjugated
bs-9754R-PE-Cy5 100 µL

ATXN7L3B Polyclonal Antibody, PE-Cy5 Conjugated

Ask
View Details
Antithrombin III (Antithrombin-III, ATIII, PRO0309, AT3, Serpin C1, SERPINC1) (FITC) discontinued
A2298-26B-FITC 100 µL

Antithrombin III (Antithrombin-III, ATIII, PRO0309, AT3, Serpin C1, SERPINC1) (FITC) discontinued

Ask
View Details